Grace Therapeutics (NASDAQ:GRCE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Grace Therapeutics (NASDAQ:GRCE) to a hold rating in a research report sent to investors on Friday morning.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $12.00.

Grace Therapeutics Price Performance

Shares of Grace Therapeutics stock opened at $3.82 on Friday. The firm has a market cap of $59.10 million, a price-to-earnings ratio of -6.16 and a beta of 0.55. The stock has a 50-day simple moving average of $3.41 and a 200-day simple moving average of $3.22. Grace Therapeutics has a 52-week low of $1.75 and a 52-week high of $3.99.

Grace Therapeutics (NASDAQ:GRCE) last posted its earnings results on Thursday, November 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). As a group, equities research analysts predict that Grace Therapeutics will post -1.06 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Stratos Wealth Partners LTD. bought a new stake in shares of Grace Therapeutics in the fourth quarter valued at approximately $39,000. SeaCrest Wealth Management LLC acquired a new stake in Grace Therapeutics in the 3rd quarter worth $42,000. Millington Financial Advisors LLC bought a new position in shares of Grace Therapeutics during the 2nd quarter worth about $59,000. Palumbo Wealth Management LLC acquired a new position in shares of Grace Therapeutics during the second quarter valued at about $144,000. Finally, ADAR1 Capital Management LLC lifted its stake in shares of Grace Therapeutics by 98.4% in the third quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock valued at $1,043,000 after buying an additional 173,823 shares during the period. 6.08% of the stock is owned by institutional investors.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.